Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).

Pastor, Natalia; Betlloch, Isabel; Pascual, José C.; Blanes, Mar; Bañuls, José; Silvestre, J.F.

doi:10.1111/j.1365-2230.2005.01972.x

Cited by 37 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have now been several case reports in the literature of successful treatment of PG using etanercept, regardless of short-term therapy or maintenance treatment. None of these case reports mentioned loss of efficacy during treatment with etanercept (7,(11)(12)(13). Recently, Lecluse et al demonstrated that in patients with psoriasis high titers of antibodies to adalimumab and low adalimumab trough concentrations are associated with poor clinical outcome.…”

Section: Commentmentioning

confidence: 93%

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Kleinpenning

Langewouters

Kerkhof

et al. 2010

Journal of Dermatological Treatment

View full text Add to dashboard Cite

In concordance with previous results of several other studies, reviews and case reports, we presume that possibly both etanercept and adalimumab could be excellent therapeutic alternatives in the treatment of PG. Unfortunately, the effectiveness of both etanercept and adalimumab were very limited in our case. Literature research revealed no other successful studies on the off-label use of other immunomodulators as an alternative treatment option for PG. However, infliximab or ustekinumab could be alternative treatment options.

show abstract

Section: Commentmentioning

confidence: 93%

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Kleinpenning

Langewouters

Kerkhof

et al. 2010

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Etanercept has also been successfully used in some cases of PG without underlying IBD [79,80,81]. In addition, another patient, allergic to infliximab, responded to adalimumab after prior failure of etanercept [82].…”

Section: Discussionmentioning

confidence: 99%

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-α antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn’s-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.

show abstract

“…Etanercept has also been successfully used in some cases of PG without underlying IBD [77, 78]. However, the value of a molecule that has less effect on digestive disease in CD-associated PG is still controversial [48].…”

Section: Treatmentmentioning

confidence: 99%

Extraintestinal Manifestations of Crohn’s Disease

et al. 2007

View full text Add to dashboard Cite

In each case of extraintestinal manifestations of Crohn’s disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy – axial arthropathy – and primary sclerosing cholangitis, which have also been described in quiescent Crohn’s disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn’s disease have been developed in the past and only the role of infliximab has increased in Crohn’s disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept and cyclosporine or tacrolimus. Unfortunately, because of the paucity of data in this field, the best evidence presented and discussed in this article for the treatment of these extraintestinal manifestations is extrapolated from patients that for the most part did not suffer from Crohn’s disease.

show abstract

Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).

Cited by 37 publications

References 1 publication

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Extraintestinal Manifestations of Crohn’s Disease

Contact Info

Product

Resources

About